picto SniZtop

Chew...
then breathe!

Sniztop®
the clinically proven solution

SniZtop® has been proven in 2 clinical studies.
More than 300 patients tested SniZtop® and the results are very conclusive.

Allergic rhinitis

Atopic dermatitis

The efficacy of SniZtop® on the reduction of rhinitis symptoms acutely experienced by subjects upon exposure to a cocktail of common outdoor and indoor allergens has been proven in a randomized, double-blind, crossover, placebo-controlled study (N=43).

Subjects were exposed (by inhalation) to a standardized allergenic challenge followed by the intake of 2 tablets of SniZtop® or placebo.
Measurements were taken every 15 min, for 2 hours.

Dust
mites

Trees
pollen

Grass
pollen

Dog & cat
dander

point

PRIMARY ENDPOINTS

Objective measurement
of the nasal congestion
(Peak Nasal Inspiratory Flow - PNIF)

point

SECONDARY ENDPOINTS

Subjective measurement
of nasal & eyes symptoms
(Visual analogue scale (VAS) score)

point

TERTIARY ENDPOINTS

Adverse Event Analysis

Fast-acting solution

fast acting

SniZtop® provides allergy relief within 10 to 15 minutes.

Comparison of Allergy Symptom Scores during the 120-minute follow-up vs placebo

allergy symptoms relieved

All bothersome allergy symptoms were significantly reduced.
Subjects' perceived feeling of well-being was highly improved.

SniZtop® efficacy on the alleviation of eczematous lesions, itching sensation and on improvement within the quality of life in patients with Atopic Dermatitis (N=281).


Subjects were divided in 4 groups:


  • 28 subjects < 5 years old
  • 78 subjects betweeen 5 and 12 years old
  • 35 subjects between 12 and 18 years old
  • 140 subjects > 18 years old

Doses were from 1 to 4 tablets per day, and adjusted to the severity of clinical symptoms and the age of the patient.


The whole observation period lasted 8 weeks with follow up visit every 4 weeks.

point

PRIMARY ENDPOINTS

Surface of skin affected

point

SECONDARY ENDPOINTS

SCORAD score
(index dedicated to the diagnosis, treatment, and management
of Atopic Dermatitis)

point

TERTIARY ENDPOINTS

Itching sensation, sleep disorders,
oedema, redness, erosions
and lichenification

Skin lesions evolution between the 1st and 2nd visit

atopic dermatitis clinical study

Sniztop® significantly improved all symptoms of atopic dermatitis with a reduction of the itching sensation in 80% of patients
within 1 month of treatment.



Quality of sleep has also been consequently improved in 79% of young children (< 5 years old).

DOWNLOAD THE DOCSHEET